Genesis Fringe: Revolutionising Healthcare: AI unleashed in pharma, medtech and IP

In collaboration with One Nucleus and their annual Genesis Conference, Marks & Clerk is delighted to be hosting a three-part seminar on Wednesday 6th December at their London office, with expert speakers from Marks & Clerk, AstraZeneca and US IP law firm Dority & Manning, P.A.  

During the event we will dig into AI patent application filings at the European Patent Office in the MedTech field, demystify the process of securing patent rights for generative AI in the U.S and discuss how the cultures, organisations and objectives of AI-focussed companies differ from their pharma partners.

•    Martin Bell - Senior Associate, Patent Attorney - Marks & Clerk
Patent filing trends in Europe for AI in MedTech

MedTech has been a rapidly growing sector for AI patent application filings. In this talk, we will dig into AI patent application filings at the European Patent Office in the MedTech field, looking at trends in allowance rate, types of technology and applicant country, and how these trends might inform patent strategy. 

•    Joseph J. Probst – Principal, Patent Attorney – Dority & Manning, P.A
AI and the Patent Puzzle: Securing Patent Rights for Generative AI in the United States

In this presentation, we'll demystify the process of securing patent rights for generative AI in the U.S. We'll highlight the benefits of generative AI technology, analyze the current legal landscape, and describe how to navigate the patent process to realize maximum returns from AI innovations. By understanding these aspects, attendees will be better equipped to protect their AI inventions and ensure their commercial success.

•    William Deacon - Senior Transaction Director - AstraZeneca 
Collaborations between AI and Pharma companies

During this talk, we’ll look at how the cultures, organisations and objectives of AI-focussed companies differ from their pharma partners. What are the pitfalls of bringing these partners together? How can the gap be bridged so that each party can apply its unique expertise to creating a valuable partnership?

Agenda – 15.45 to 18.00

15.45 - 16.30: Coffee, networking
16.30 – 16.50: Marks & Clerk talk 
16.50 -17.10: Dority & Manning, P.A talk 
17.10- 17.30: AstraZeneca talk
17.30-18.00: Q&A
18.00: Pub organised by One Nucleus TBC nearer the time.
18.00-19:30: Welcome Reception organised by One Nucleus 

Biographies of speakers 

Martin Bell – Senior Associate, Patent Attorney – Marks & Clerk
Martin Bell is a European and UK patent attorney with Marks & Clerk in Oxford. He read Chemistry at the University of Oxford, where he remained for a doctorate in Chemical Physics, applying theoretical and experimental techniques from particle physics to study fundamental chemical and physical processes.  Before joining Marks & Clerk, Martin also worked in academic research and as a software engineer for a technical consultancy firm.  His practice relates mainly to physics, mechanical, and software/AI related inventions, and he drafts and prosecutes applications in these areas for clients of all sizes, including a nuclear fusion scale-up.

Martin has particular experience of drafting and prosecuting machine learning patent applications and he enjoys working on applications with complex technical and mathematical subject matter.  He also has a keen personal and professional interest in computer science and machine learning, particularly their applications to problems in the physical and life sciences.

Joseph J. Probst – Principal, Patent Attorney – Dority & Manning, P.A
Joseph concentrates his practice in patent prosecution and portfolio management, with a primary focus on clients operating in the software industry, particularly in the realms of artificial intelligence, machine learning, and quantum computing. He consistently engages with cutting-edge AI technologies, such as Generative AI, with applications spanning across industries, from cloud computing and cybersecurity to chemicals and pharmaceuticals.

Leveraging his profound technical experience, Joseph can obtain a visceral understanding of the complex science behind a client's technology and help develop successful patent prosecution strategies that advance the client’s business goals and commercial agenda in the short and long term.

Joseph has extensive experience presenting both nationally and internationally on various topics related to AI technologies. His engaging presentations cover a variety of topics, from current legal trends around AI to intellectual property management strategies related to the same. Joseph's approach ensures that listeners not only gain valuable knowledge but also feel connected to the exciting developments in the world of artificial intelligence.

William Deacon - Senior Transaction Director - AstraZeneca 
William Deacon is a Senior Transaction Director in AstraZeneca’s Business Development Operations group, focusing on late-stage clinical licensing and M&A, collaborations and partnerships. William has a specific focus on digital and data-driven deals, recent examples include the collaborations with IBEX, Tempus and GRAIL, along with the creation of AstraZeneca’s new digital health unit, Evinova.